Berr et al. identified how genetical and pharmacological disruption of vimentin in vivo increases survival as vimentin is required for NSCLC progression, and metastasis and protects from ferroptosis (Berr et al., 2023). Here, VIM is linked to non-small cell lung carcinoma.